RxDoctor Payments Data

Donna Ott, DO

Family Medicine · Richboro, PANPI 1730124777

Payments from drug & device makers

$4,294in general payments, 2019–2025

Across 130 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$396
  • Lilly USA, LLC$225
  • E.r. Squibb & Sons, L.L.C.$224
  • AstraZeneca$192
  • Amarin Pharma, Inc.$191
  • plus $862 from 14 others

What the payments were for

  • Speaking & faculty fees$1,12526%
  • Food & beverage$3,16374%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,294 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$69,457
Medicare patients
241
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$67,219
MounjaroTirzepatide53$66,638
NuplazidPimavanserin Tartrate11$53,515
JardianceEmpagliflozin35$51,223
EliquisApixaban45$43,690
JanuviaSitagliptin Phosphate29$35,910
TrulicityDulaglutide17$29,662
Atorvastatin Calcium319$3,909
Rosuvastatin Calcium179$2,932
Levothyroxine Sodium228$2,854
Albuterol Sulfate HfaAlbuterol Sulfate97$2,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$2,226
Metoprolol Succinate93$1,909
Lisinopril165$1,818
Pantoprazole Sodium136$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$225$96,30070 claims
Novo NordiskOzempic$396$67,21952 claims
Boehringer IngelheimJardiance$132$51,22335 claims
PfizerEliquis$189$43,69045 claims
AbbVieSynthroid$2,203$89213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Richboro

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →